BEVERLY HILLS, Calif., May 27, 2014 /PRNewswire/ -- ImmunoClin Corporation (OTCBB: IMCL), is a U.S. healthcare company specializing in personalized medicine, developing strategies to fight inflammatory conditions that are the underlying cause of pathologies in multiple conditions affecting the majority of human population: infections, cancer, cardiovascular disease, and dementia, including Alzheimer's disease. ImmunoClin is pleased to appoint Professor Antony Bayer as a member of the Company's Scientific Advisory Board.
"Professor Bayer is a highly respected researcher and clinician. His substantial contribution to research of cognitive disorders distinguish him from his peers; he will undoubtedly provide unbiased clinical insight with respect to the Company's portfolio, especially in the areas of ageing and Alzheimer's disease," said Dr. Dorothy Bray, President and a CEO of ImmunoClin.
Professor Bayer is the Personal Chair, Institute of Primary Care & Public Health, for the Cardiff University School of Medicine in Cardiff, UK. He is also the Head of the Geriatric Medicine Section as well as the Director of the Memory team. He is a leading researcher in the area of dementia and has focused research on the clinical care of people with cognitive disorders, with special interest in Alzheimer's disease. Prof. Bayer is Editor of the journal 'Reviews in Clinical Gerontology' and holds various appointments, including as a member of the Scientific Advisory Board of Alzheimer Europe, Public Health Committee and Research Grants Advisory Board of the Alzheimer's Society, IAG Global Ageing Research Network, EASD Global Initiative on Diabetes in Older People, and European GERONTONET Consortium.
"I look forward to assessing ImmunoClin's functional food products as well as GARD and MIRA prognostic tests for Alzheimer's and cardiovascular diseases in clinical trials and to participating in the development of a personalized approach to manage older patients," stated Prof. Bayer.
About ImmunoClin Corporation
ImmunoClin Corporation is a healthcare company with European headquarters in London, United Kingdom and laboratories in central Paris, France. ImmunoClin concentrates its innovation on developing personalized and preventive strategies to fight inflammatory conditions that are the underlying cause of pathologies in multiple conditions affecting the majority of the human population: infections, cancer, cardiovascular disease, and dementia, including Alzheimer's disease.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of technologies, pharmaceuticals, and food products. ImmunoClin Corporation does not undertake any duty nor does it intend to update the results of these forward-looking statements.
J. Scott Munro, CFO
Cell: +1 778-987-4308
SOURCE ImmunoClin Corporation